Dipyridamole modulates the innate immune response during human endotoxemia
© Ramakers et al. 2011
Published: 1 March 2011
Previous studies have shown that the endogenous nucleoside adenosine is able to modulate inflammation and to prevent associated organ injury. Dipyridamole, an adenosine re-uptake inhibitor, increases extracellular adenosine concentrations during unfavorable conditions (for example, inflammation), and as such may modulate the inflammatory response. We examined the effects of dipyridamole treatment on innate immunity during human experimental endotoxemia.
In a randomized double-blind placebo-controlled study, 20 healthy subjects received 2 ng/kg Escherichia coli endotoxin intravenously following 7-day pretreatment with dipyridamole, 200 mg retard twice daily, or placebo.
Dipyridamole treatment increases adenosine concen-trations during systemic inflammation associated with an augmented anti-inflammatory response and a faster decline in TNFα during human experimental endotoxemia.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.